UK claims successes in meeting cancer and CVD mortality reduction targets
This article was originally published in Clinica
England is claiming early successes in meeting its targets for reducing cancer- and cardiovascular disease-related mortality among the under-75s. The annual update announced today by the Department of Health, which includes 2005-07 data, features: an 18.2% fall (since the baseline) in three-year average mortality rates for cancer, which is said to be on course to meet the 20% reduction target by 2009-11; and a 44% cut in three-year average mortality rates for circulatory diseases, thereby meeting ahead of schedule the minimum target of 40% by 2009-11, claims the DH.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.